As a leading independent diagnostic laboratory, Labcorp participates in a highly attractive duopoly that offers favorable prospects as healthcare moves toward reformed payment models and enjoys a reprieve from scheduled cuts to Medicare reimbursement under the Protecting Access to Medicare Act, and as potentially positive M&A opportunities remain plentiful.